Resistance to certain cancer therapies may be caused by loss of anti-tumour protein : StudyhealthUpdated: Dec 27, 2020, 12:50 ISTAccording to Penn State College of Medicine researchers, the absence of a protein that works to prevent tumour formation may explain why some patients are resistant to common cancer therapy. Douglas Stairs, assistant professor of pathology and laboratory medicine and pharmacology, investigated why these patients may be resistant to EGFR therapies. “Our previous work showed that too much EGFR and reduced amounts of a protein called p120 catenin (p120ctn) can cause cancer to develop. According to Stairs, scientists know that the cancer cells often have reduced amounts of p120ctn, but are unsure why. Cells with high amounts of EGFR died when treated with the therapies, while those with normal amounts of EGFR were not affected by the therapies.

Source: Hindustan Times December 27, 2020 07:21 UTC